US5783187A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of cell proliferative disorders using antibodies which bind connective tissue growth factor
Assignee: University of South Florida St. Petersburg
•
Filing: 1996-09-11
•
Granted: 1998-07-21
•
Expires: 2016-09-11
Abstract
Abstract Connective Tissue Growth Factor (CTGF) is a polypeptide growth factor for connective tissue cells. CTGF is related immunologically and biologically to PDGF, but is the product of a distinct gene. CTGF, nucleic acids encoding CTGF, means for producing CTGF, anti-CTGF antibodies, diagnostic and therapeutic methods for using CTGF, and methods for inhibition or stimulation of CTGF activity are disclosed.
Inventors
- 👤 Gary R. Grotendorst
- 👤 Douglas M. Bradham, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 11:03
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/22; C07K14/00; C07K14/435; C07K14/475; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/12
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
57 words
A method for ameliorating a cell proliferative disorder associated with Connective Tissue Growth Factor (CTGF), comprising administering to a subject having said disorder, at the site of the disorder, a composition comprising a therapeutically effective amount of an antibody or fragment thereof that binds to CTGF, wherein said antibody or fragment thereof does not bind to PDGF.
Claim 2
Independent Claim
57 words
A method for ameliorating a cell proliferative disorder associated with Connective Tissue Growth Factor (CTGF), comprising administering to a subject having said disorder, at the site of the disorder, a composition comprising a therapeutically effective amount of an antibody or fragment thereof that binds to CTGF, wherein said antibody or fragment thereof does not bind to PDGF.
Claim 3
Dependent Claim
16 words
The method of claim 1, wherein the cell proliferative disorder is due to overgrowth of cells.
Claim 4
Dependent Claim
18 words
The method of claim 1, wherein the cell proliferative disorder is due to overgrowth of connective tissue cells.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-07-20 | 2002-01-19 | 2002-07-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-07-20 | 2006-01-19 | 2006-07-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-07-20 | 2010-01-19 | 2010-07-21 | $7700.00 | Window Closed / Lapsed |